Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia
- PMID: 9764553
- DOI: 10.1007/BF01691133
Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia
Abstract
A study was performed in low-risk cancer patients with chemotherapy-induced febrile neutropenia to determine the safety and efficacy of ceftriaxone given in an outpatient setting. A total of 126 episodes of febrile neutropenia in 120 clinically stable outpatients were treated with intravenous ceftriaxone alone (n=100) or in combination with other antibiotics (n=26). The mean neutrophil count was 460/mm3; severe neutropenia (< 100/mm3) was observed in 18 episodes. The initial treatment with ceftriaxone (alone or in combination) was successful in 99 episodes (78%). Ninety-five episodes (76%) were successfully treated in an outpatient setting only; admission to hospital was necessary in 31 episodes (24%), but no infection-related death was observed. Ceftriaxone seems to be safe and effective for outpatient therapy of patients with low-risk febrile neutropenia.
Similar articles
-
Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia.Chemotherapy. 1998 Sep-Oct;44(5):343-54. doi: 10.1159/000007134. Chemotherapy. 1998. PMID: 9732151 Clinical Trial.
-
Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.Med Pediatr Oncol. 2000 Feb;34(2):87-91. doi: 10.1002/(sici)1096-911x(200002)34:2<87::aid-mpo2>3.0.co;2-f. Med Pediatr Oncol. 2000. PMID: 10657866 Clinical Trial.
-
Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.J Microbiol Immunol Infect. 2009 Apr;42(2):141-7. J Microbiol Immunol Infect. 2009. PMID: 19597646 Clinical Trial.
-
New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?Chemotherapy. 1998 Nov-Dec;44(6):427-35. doi: 10.1159/000007155. Chemotherapy. 1998. PMID: 9755304 Review.
-
Ceftriaxone in febrile neutropenia.J Chemother. 2003 Jun;15(3):211-9. doi: 10.1179/joc.2003.15.3.211. J Chemother. 2003. PMID: 12868545 Review.
Cited by
-
Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.Cochrane Database Syst Rev. 2019 Mar 19;3(3):CD009031. doi: 10.1002/14651858.CD009031.pub2. Cochrane Database Syst Rev. 2019. PMID: 30887505 Free PMC article.
-
The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.Infect Dis Ther. 2022 Dec;11(6):2063-2098. doi: 10.1007/s40121-022-00700-1. Epub 2022 Oct 14. Infect Dis Ther. 2022. PMID: 36229765 Free PMC article.
-
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.Support Care Cancer. 2008 Sep;16(9):1017-23. doi: 10.1007/s00520-007-0383-z. Epub 2008 Jan 15. Support Care Cancer. 2008. PMID: 18197434 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical